Lupin Limited has informed the Exchange that the Company has entered into a License and Supply Agreement with Zentiva, a.s., for commercialization of Lupin s biosimilarCertolizumab Pegol.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Midcap 150 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lupin has signed a License and Supply Agreement with Zentiva, a Czech Republic-based pharma company, to commercialize its biosimilar Certolizumab Pegol across multiple international markets, excluding Australia, Japan, Brazil, Philippines, and India. Lupin will handle development, manufacturing, and supply, and will directly commercialize the product in the USA, Canada, and other remaining regions. Zentiva will drive commercialization in Europe and CIS markets, using its existing commercial and regulatory network. Under the deal, Zentiva will pay Lupin up to USD 50 million in milestone-linked fees, including USD 10 million upfront, with both companies sharing profits from their respective markets and jointly investing in development. The transaction is not a related party deal and involves no acquisition of any entity.
This is a positive development for shareholders, as it gives Lupin a low-cost entry into European and CIS markets through an established partner while bringing in immediate cash inflow of USD 10 million and potential upside of up to USD 50 million in milestones. The profit-sharing structure and expanded geographic reach could support future revenue growth in Lupin's biosimilars portfolio, though actual contribution depends on regulatory approvals and product launches in the covered territories.